Previous 10 |
home / stock / gnmsf / gnmsf news
Genmab ( OTCPK:GNMSF ): FY Operating income of DKK1.34B. More news on: Genmab A/S, Genmab A/S ADR, Earnings news and commentary, Tech stocks news, Read more ...
Company Announcement Copenhagen, Denmark; February 21, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today its Annual Report for 2017. Below is a summary of business progress and financial performance for the year, and financial outlook for ...
Note: Subscribers to Avisol Capital Partners' Total Pharma Tracker got an early look at this publication. Consider becoming a subscriber today to get early access! Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep p...
Company Announcement Net sales of DARZALEX in 2017 totaled USD 1,242 million Genmab receives royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 23, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) an...
Citing low the low number of chronic lymphocytic leukemia (CLL) being treated with Arzerra (ofatumumab) outside of the U.S., Novartis (NYSE: NVS ) will transition the product from commercial availability to limited availability via compassionate use programs in all ex-U.S. markets. More ...
Company Announcement Novartis intends to transition the commercial availability of Arzerra to limited availability via compassionate use programs for treatment of CLL in non-US markets. Novartis will continue to market for CLL in the US Novartis will work with r...
Company Announcement U.S. FDA grants Priority Review to daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant May 21, 2018 PDUFA date ...
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; January 9, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 29 of the Danish Securities Trading Act that Artisan Partners Limited Partn...
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...